Objective: To analyze the results of the first two years of application of the clinical pathway for transurethral resection (TUR) of bladder tumors at La Paz University Hospital.
Methods: We developed a clinical pathway of 4 hospital stays (5 days) for TUR of the bladder that included the following: matrix-verification, treatments prescribed, verification of changes, patient information sheet and patient satisfaction questionnaire. The information for the evaluation of the results were obtained from the pathway records and data on the activities of the Urology services. To assess the results for efficiency in the use of resources, the mean duration of hospital stay of patients in the pathway were compared with that of a control group comprised of 50 randomly selected patients submitted to TUR of the bladder in 1997.
Results: From June 1998 to May 2000, 481 of the 494 (97.4%) treated patients entered the clinical pathway.
Conclusions: In our experience, the clinical pathway for the urinary bladder is a useful instrument for developing the clinical management of this condition. It reduces the unwanted changes in patient care and hospital stay, carries a low incidence of complications and readmissions, and achieves a high degree of patient satisfaction.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Exploring the influence of health and digital health literacy on quality of life and follow-up compliance in patients with primary non-muscle invasive bladder cancer: a prospective, single-center study.
World J Urol
January 2025
School of Medicine, Department of Urology, Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Fahrettin Kerim Gökay Cd., Istanbul, 34720, Turkey.
Objective: Given the increasing significance of digital health literacy (DHL) and health literacy (HL) in promoting informed decision-making and healthy behaviors, this study aimed to assess the influence of self-reported HL and DHL on treatment adherence and quality of life among patients who underwent transurethral resection of bladder tumors (TUR-BT) for primary non-muscle invasive bladder cancer (NMIBC).
Materials & Methods: This single-center observational study involved patients who underwent TUR-BT for NIMBC at a tertiary hospital from May 2022 to February 2024. Before the procedure, the patients' DHL and HL were evaluated using the European Health Literacy Survey Questionnaire short version and the eHealth Literacy Scale.
Utility of MRI in NMIBC and feasibility of avoiding Re-TURB in carefully selected patients: a systematic review.
World J Urol
January 2025
Department of Urology, Paris Saint-Joseph Hospital, Paris, France.
Objective: This systematic review was conducted to synthesize current research on the role of repeated transurethral resection of the bladder (re-TURB) and the emerging use of magnetic resonance imaging (MRI) in discerning patient suitability for safely foregoing this procedure.
Evidence Acquisition: Employing a methodical literature search, we consulted several bibliographic databases including PubMed, Science Direct, Scopus, and Embase. The review process adhered strictly to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines.
Evaluating the Performance of ChatGPT-4o Oncology Expert in Comparison to Standard Medical Oncology Knowledge: A Focus on Treatment-Related Clinical Questions.
Cureus
January 2025
Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul, TUR.
Integrating artificial intelligence (AI) into oncology can revolutionize decision-making by providing accurate information. This study evaluates the performance of ChatGPT-4o (OpenAI, San Francisco, CA) Oncology Expert, in addressing open-ended clinical oncology questions. Thirty-seven treatment-related questions on solid organ tumors were selected from a hematology-oncology textbook.
View Article and Find Full Text PDFPredictive value of Bladder EpiCheck in detecting residual tumor before second TUR for non-muscle-invasive bladder cancer.
World J Urol
January 2025
Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, 34200, Turkey.
Purpose: As Bladder EpiCheck (BE) is a promising urinary biomarker for diagnosis and follow up of non-muscle-invasive bladder cancer (NMIBC), there are no studies evaluated this tool for second transurethral resection (TUR) indication. We aim to evaluate the performance of BE in predicting residual tumor before second TUR in NMIBC and its effects on clinical decision making.
Methods: A total of 50 patients who were diagnosed with NMIBC and indicated for a second TUR were included in the study prospectively.
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer.
J Egypt Natl Canc Inst
December 2024
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Background: Tumor recurrence or metastasis after surgery is a significant factor influencing bladder cancer (BC) prognosis. Novel molecular biomarkers are necessary to determine each patient's specific outcome because current biomarkers have limited power for predicting prognosis. The proto-oncogene MET encodes c-MET, a tyrosine kinase receptor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!